Citation Tools
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)